noom weight loss glp 1 offers cut-price compounded GLP-1 drug for obesity Why We Launched Noom GLP-1RX
Description
A 17% Reduction in Overall Cancer Risk A landmark study published in JAMA Oncology (Dai H et al., August 2025), drawing on data from 14 health systems encompassing approximately 20 million patients, found that adults with obesity who were prescribed GLP-1 receptor agonists had a 17% lower risk of developing cancer compared to carefully matched non-users
September 27, 2024
2013 Jan;37(1):18-36
Transactivation of epidermal growth factor receptor (EGFR) by GLP-1R occurs via c-Src, which induces phosphoinositide 3-kinase (PI3K) signalling [28] and prevents premature pancreatic cell apoptosis via upregulation of Bcl2 and inhibition of caspase-3 and forkhead box protein 1 (FoxO1) [28], thereby leading to disinhibition of PDX-1 [28]
Modulation of immune homeostasis by commensal bacteria
Semaglutide, marketed as Ozempic, Wegovy, and Rybelsus, has transformed treatment for type 2 diabetes and obesity
